Published in PLoS One on May 27, 2009
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
Early steps in primary cilium assembly require EHD1/EHD3-dependent ciliary vesicle formation. Nat Cell Biol (2015) 2.53
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov (2012) 1.97
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol (2010) 1.38
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Analysis of the genome to personalize therapy for melanoma. Oncogene (2010) 1.33
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood (2011) 1.28
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis (2011) 1.20
A melanoma molecular disease model. PLoS One (2011) 1.15
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene (2012) 1.15
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget (2015) 1.06
Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res (2014) 1.05
Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. J Biol Chem (2014) 0.96
Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies. Oncotarget (2014) 0.95
Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon. Am J Physiol Gastrointest Liver Physiol (2014) 0.92
Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. Dermatol Res Pract (2011) 0.91
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res (2014) 0.90
Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep (2012) 0.89
Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle (2012) 0.89
Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am (2011) 0.89
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations. Hum Pathol (2013) 0.89
Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res (2014) 0.88
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther (2013) 0.88
New treatments for metastatic melanoma. CMAJ (2014) 0.87
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol Cancer (2015) 0.87
Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation. J Biol Chem (2013) 0.86
The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol (2012) 0.86
Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol (2015) 0.86
Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway. Cancer Res (2013) 0.85
Oncogene mutational profile in nasopharyngeal carcinoma. Onco Targets Ther (2014) 0.85
Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling. PLoS One (2013) 0.85
Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res (2014) 0.85
Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. J Invest Dermatol (2015) 0.84
Emerging phytochemicals for prevention of melanoma invasion. Cancer Lett (2013) 0.84
Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. Oncotarget (2015) 0.83
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer (2012) 0.82
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front Oncol (2015) 0.82
Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther (2014) 0.81
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. Oncotarget (2016) 0.80
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget (2016) 0.77
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Devel Ther (2015) 0.77
Searching for the Chokehold of NRAS Mutant Melanoma. J Invest Dermatol (2016) 0.77
Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma? J Skin Cancer (2011) 0.76
DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer. Cancer Med (2017) 0.75
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science (1993) 4.76
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res (2006) 2.84
The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer (2005) 2.83
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res (2008) 2.76
Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ (2008) 2.44
New insight into BRAF mutations in cancer. Curr Opin Genet Dev (2007) 2.40
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell (2005) 2.39
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol (2004) 2.32
K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res (2007) 2.26
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther (2007) 2.02
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet (2005) 1.90
Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res (2009) 1.57
Pten, tumorigenesis, and stem cell self-renewal. Cell (2006) 1.36
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer (2007) 1.31
Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene (2007) 1.27
pHUSH: a single vector system for conditional gene expression. BMC Biotechnol (2007) 1.27
Raf kinases: oncogenesis and drug discovery. Int J Cancer (2006) 1.25
The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol (2007) 1.14
Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther (2006) 1.10
Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Top Med Chem (2007) 1.06
Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell Cycle (2006) 1.01
Targeting oncogenic Ras. Genes Dev (2007) 1.01
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature (2004) 12.41
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol (2006) 6.82
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res (2005) 4.94
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
MazF cleaves cellular mRNAs specifically at ACA to block protein synthesis in Escherichia coli. Mol Cell (2003) 4.63
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature (2009) 4.12
Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature (2003) 3.96
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res (2008) 3.93
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res (2009) 3.72
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol (2008) 3.36
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
A specificity map for the PDZ domain family. PLoS Biol (2008) 3.16
Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res (2006) 3.12
The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res (2003) 2.91
CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell (2006) 2.89
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res (2006) 2.84
Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med (2002) 2.81
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
Pannexin-1 is required for ATP release during apoptosis but not for inflammasome activation. J Immunol (2011) 2.67
Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res (2007) 2.57
The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res (2012) 2.19
B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol (2010) 2.17
Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06
The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer (2013) 2.05
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Phosphorylation of NLRC4 is critical for inflammasome activation. Nature (2012) 1.92
Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J Immunol (2008) 1.92
Rapid evolution of functional complexity in a domain family. Sci Signal (2009) 1.85
Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples. BMC Med Genomics (2011) 1.84
Bayesian modeling of the yeast SH3 domain interactome predicts spatiotemporal dynamics of endocytosis proteins. PLoS Biol (2009) 1.78
PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell (2010) 1.75
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res (2009) 1.70
Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res (2005) 1.69
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science (2006) 1.64
ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther (2012) 1.55
IL-27 promotes T cell-dependent colitis through multiple mechanisms. J Exp Med (2010) 1.54
DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury. Proc Natl Acad Sci U S A (2013) 1.53
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature (2013) 1.52
PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discov (2011) 1.50
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res (2012) 1.47
Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. Proc Natl Acad Sci U S A (2009) 1.46
p21-activated kinase 1: PAK'ed with potential. Oncotarget (2011) 1.44
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41
IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J Exp Med (2010) 1.41
FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One (2011) 1.35
Coevolution of PDZ domain-ligand interactions analyzed by high-throughput phage display and deep sequencing. Mol Biosyst (2010) 1.35
Kinome siRNA screen identifies regulators of ciliogenesis and hedgehog signal transduction. Sci Signal (2008) 1.33
p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res (2012) 1.32
Comparison of sequencing platforms for single nucleotide variant calls in a human sample. PLoS One (2013) 1.28
pHUSH: a single vector system for conditional gene expression. BMC Biotechnol (2007) 1.27
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res (2012) 1.27
Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. Nat Immunol (2013) 1.24
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A (2012) 1.22
Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res (2009) 1.21
DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res (2012) 1.16
The STARD9/Kif16a kinesin associates with mitotic microtubules and regulates spindle pole assembly. Cell (2011) 1.16
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol (2012) 1.15
Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. J Exp Med (2009) 1.14
High-throughput, high-accuracy array-based resequencing. Proc Natl Acad Sci U S A (2009) 1.14
Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detection. Nat Methods (2007) 1.10
Characterization of dual substrate binding sites in the homodimeric structure of Escherichia coli mRNA interferase MazF. J Mol Biol (2005) 1.10
Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells. Cancer Res (2013) 1.09
FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res (2012) 1.08
p21-Activated kinase inhibitors: a patent review. Expert Opin Ther Pat (2012) 1.07
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med (2011) 1.06
Discovering cancer genes by integrating network and functional properties. BMC Med Genomics (2009) 1.05
Targeting cancer with kinase inhibitors. J Clin Invest (2015) 1.05